Orforglipron vs. semaglutide for weight loss

Orforglipron (Foundayo) is among the newest entries to the GLP-1 market for weight loss. How does it stack up against semaglutide (Wegovy, Ozempic)? 

Keep reading for a comprehensive breakdown of orforglipron vs. semaglutide, including differences in cost, dosage schedules, side effects, and approved indications.

Key differences between orforglipron and semaglutide include how they're taken, the conditions they're approved to treat, and their efficacy for weight loss — semaglutide, in the form of Wegovy, produces greater weight loss.

Orforglipron is a daily tablet made by Eli Lilly that is available under the brand name Foundayo. It is currently FDA-approved for weight loss, in combination with diet and exercise, in adults with obesity or with overweight and a weight-related health condition.

Semaglutide is an oral and injectable medication made by Novo Nordisk. It’s available under various brand names that are approved for different indications, when used in combination with diet and exercise:

• Ozempic is a weekly injection or daily pill. Both forms are approved to treat type 2 diabetes in adults and reduce cardiovascular risk in adults with type 2 diabetes and heart disease. The injectable form is also approved to reduce the risk of kidney decline in adults with type 2 diabetes and chronic kidney disease.

• Wegovy is a weekly injection or daily pill. Both forms are approved for weight loss in adults with obesity or with overweight and a weight-related health condition, and for cardiovascular risk reduction in adults with heart disease and obesity or overweight. The injection is also approved for fatty liver disease in certain adults and weight loss in children 12 years and older with obesity. 

*Terms and restrictions may apply for certain doses

See if you qualify

Whether orforglipron or semaglutide is more effective depends on which form of semaglutide you're taking. Both injectable and oral Wegovy appear to produce greater weight loss than orforglipron. For blood sugar control, injectable semaglutide (Ozempic) outperforms orforglipron. For either condition, orforglipron is more effective than the Ozempic pill.

Which is more effective for weight loss and weight management?

Semaglutide appears to be more effective for weight loss than orforglipron when taken at dosages approved for weight loss. In an analysis of separate clinical trials involving people with obesity, the Wegovy pill (oral semaglutide 25 mg) led to about 3 percentage points more weight loss than the highest dose of orforglipron.

But the more effective option for weight loss may also depend on whether or not you have diabetes. In a 2026 trial that compared the drugs in people with type 2 diabetes:

• People on orforglipron lost 9.2% of their starting body weight in 52 weeks, on average.

• People on the Ozempic pill (formerly Rybelsus) lost 5.3% of their starting weight in the same timeframe.

Here’s a look at other clinical trials where each drug was compared to placebo:

• Wegovy injection: People lost 14.9% of their starting body weight with the 2.4 mg dose in 68 weeks  and ~19% with the 7.2 mg dose (Wegovy HD) in 72 weeks.

• Wegovy pill: People lost 13.6% of their starting body weight in 64 weeks.

• Ozempic injection: People with type 2 diabetes lost 7% of their starting body weight in 68 weeks on the 1 mg dose.

• Ozempic pill: People with type 2 diabetes lost 2.6%–4.2% of their starting body weight in 26 weeks. 

• Orforglipron: People lost 7.5%–11.2% of their starting body weight in 72 weeks, depending on the dose. 

For context, placebo groups typically show around 2% weight loss in these trials. It’s also worth noting that people with type 2 diabetes often lose less weight on GLP-1s than non-diabetic people with obesity, possibly because of differences in metabolism.

Which is more effective for blood sugar control?

When comparing orforglipron and semaglutide for blood sugar control, only semaglutide is FDA-approved for managing type 2 diabetes. Foundayo is currently approved only for weight loss, but it is under investigation for diabetes management

Research suggests orforglipron may be more effective at lowering blood sugar levels than the Ozempic pill, based on a head-to-head trial in adults with type 2 diabetes. After 52 weeks, average reductions in blood sugar levels (measured using HbA1c) were as follows, depending on the dose:

• Orforglipron lowered HbA1c by 1.71%–1.91%.

• The Ozempic pill lowered HbA1c by 1.23%–1.47%. 

Injectable semaglutide — specifically, Ozempic — may lower blood sugar levels more than orforglipron, although no studies have directly compared them. In separate clinical trials, injectable Ozempic lowered HbA1c levels by 1.9%–2.2% in 40 weeks, depending on the dose.

Although orforglipron and semaglutide are different active ingredients, both are GLP-1 receptor agonists and work similarly in the body:

• They slow stomach emptying, which promotes feelings of fullness sooner and for longer.

• They decrease appetite — and consequently food intake — by targeting areas of the brain involved in appetite regulation.

• They lower blood sugar levels by stimulating insulin release while limiting glucagon (a hormone that raises blood sugar).

Both orforglipron and semaglutide follow a gradual titration schedule, in which a healthcare provider starts at a low dosage and increases it approximately every month until reaching a maintenance dosage. This approach is designed to help the body adjust to the medication and minimize side effects.

Orforglipron 

Orforglipron is an oral tablet taken once daily.

How to take it: Take orforglipron by mouth, with or without food. It can be taken at any time of day, though choosing a consistent time may be helpful. In clinical trials, it was taken in the morning.

Doses: Orforglipron is available in six dosage strengths: 0.8 mg, 2.5 mg, 5.5 mg, 9 mg, 14.5 mg, and 17.2 mg. 

Starting dose: 0.8 mg

Maintenance doses: 5.5 mg, 9 mg, 14.5 mg, 17.2 mg 

Maximum dose: 17.2 mg 

Dosing schedule: Orforglipron is taken daily, with dose increases typically occurring every 30 days until you reach an effective maintenance dosage. 

Semaglutide 

Semaglutide comes in both oral and injectable forms. The oral tablets are taken daily while the injections are administered weekly.

How to take it: Oral semaglutide is taken by mouth on an empty stomach in the morning, at least 30 minutes before eating, drinking, or taking other medications, and swallowed whole with up to 4 ounces of water. Injectable semaglutide is administered subcutaneously (under the skin) in the abdomen, thigh, or upper arm on the same day each week, rotating injection sites each week.

Doses: 

• The Ozempic pill is available in three dosage strengths: 1.5 mg, 4 mg, and 9 mg.  

• The Ozempic injection is available in four dosage strengths: 0.25 mg, 0.5 mg, 1 mg, and 2 mg. 

• The Wegovy pill is available in four dosage strengths: 1.5 mg, 4 mg, 9 mg, and 25 mg. 

• The Wegovy injection is available in six dosage strengths: 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg, and 7.2 mg.

Starting dose: 0.25 mg (injection), 1.5 mg (pill)

Maintenance doses: 0.5 mg, 1 mg, 2 mg (Ozempic injection); 4 mg, 9 mg (Ozempic pill); 25 mg (Wegovy pill); 1.7 mg, 2.4 mg, 7.2 mg (Wegovy injection)

Maximum dose: 9 mg (Ozempic pill), 2 mg (Ozempic injection), 25 mg (Wegovy pill), 7.2 mg (Wegovy injection)

Dosing schedule: Oral semaglutide is taken daily, with dosage increases occurring every 30 days until you reach an effective maintenance dosage. Injectable semaglutide is taken weekly, with dosage increases every four weeks until you reach an effective maintenance dosage.

Since they’re both GLP-1s, orforglipron and semaglutide share many of the same side effects.

With either medication, GI-related side effects typically range from mild to moderate and are most common when starting the medication or increasing the dose.

Semaglutide and orforglipron also carry similar risks and potentially serious side effects, including:

• Acute pancreatitis

• Diabetic retinopathy complications (diabetes-related vision changes)

• Hypoglycemia (low blood sugar), especially when used with insulin

• Kidney or gallbladder issues

• Severe gastrointestinal reactions

• Allergic reactions

• Pulmonary aspiration during general anesthesia or deep sedation

As GLP-1 receptor agonists, both medications carry a boxed warning for thyroid tumors based on animal studies; whether GLP-1 receptor agonists carry the same risk in humans is not yet known. People with a personal or family history of thyroid cancer should not take semaglutide or orforglipron. 

Without insurance, orforglipron (Foundayo) generally costs less than semaglutide — although it depends on the dose and the brand of semaglutide (Ozempic or Wegovy).

Orforglipron 

Without insurance, orforglipron costs $149–$299 per month, depending on the dose, on Ro. This pricing reflects the manufacturer offer, which requires a refill for the 14.5 mg and 17.2 mg doses within 45 days of the last fill; without the offer, those doses cost $349 per month.  

Here’s a breakdown of the cash prices for orforglipron:

• 0.8 mg dose: $149 per month

• 2.5 mg dose: $199 per month

• 5.5 mg and 9 mg doses: $299 per month

• 14.5 mg and 17.2 mg doses: $299 per month (with manufacturer offer) or $349 per month 

For those with commercial drug insurance that covers orforglipron, the manufacturer's savings offer may reduce the cost to as little as $25 per month. For those without coverage, the same card allows access to the cash prices listed above.

Semaglutide 

Without insurance, semaglutide costs $149 to $1,349.02 or more per month, depending on the dose, form, and where it's filled. 

Those who are uninsured, who have a commercial plan that doesn't cover the medication, or simply prefer to pay cash may be eligible to pay the cash prices on Ro listed below. Without coverage, the list price is $1,349.02 for Wegovy and $1,027.51 for Ozempic. Retail pharmacy prices may be higher than the list price.

Here’s a breakdown of the cash prices for semaglutide on Ro, starting with the least expensive:

*This price is available through a limited-time offer (see more here). Terms and restrictions may apply for certain doses.

If you have commercial drug insurance that covers Ozempic, you may be able to get a one-, two-, or three- month refill for as low as $25 per month with the manufacturer savings offer. 

If you have commercial drug insurance that covers Wegovy, you may be able to get it for as low as $25 per month with the manufacturer savings offer.

Your healthcare provider can help you decide whether orforglipron or semaglutide is the right fit for you, based on your health goals and personal medical history.

Orforglipron may be better if:

• You like the routine of a daily pill

• You pay cash for your prescriptions

• Your insurance covers Foundayo

Semaglutide may be better if:

• You prefer the flexibility of only having to do an injection once a week

• You also have heart disease, fatty liver disease, or chronic kidney disease

• Your insurance covers Wegovy or Ozempic

Get started

While orforglipron and semaglutide work similarly to produce weight loss along with lifestyle changes, they have several key differences, including:

• What they treat. Orforglipron is only approved for weight loss, semaglutide is also approved for managing type 2 diabetes, cardiovascular risk reduction, fatty liver disease, and chronic kidney disease.

• How effective they are for weight loss. The average weight loss for Wegovy is 13.6%–18.8%, compared with 7.5%–11.2% for orforglipron.

• How they’re taken. Orforglipron is a daily pill you can take any time of day, with or without food. Injectable semaglutide is taken weekly, whereas oral semaglutide has strict timing requirements.

• How much they cost. Without insurance, orforglipron is the most affordable option, costing $149–$299. The Ozempic and Wegovy pills have similar pricing, but injectable semaglutide can cost more.